November 22, 2023

Adjuvant Everolimus Improves Recurrence-Free Survival in Very High–Risk Renal Cell Carcinoma

A secondary analysis from the phase III SWOG S0931 EVEREST trial found that adjuvant everolimus given to patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectom...

The ASCO Post

January 30, 2024

Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma

In a study presented at the 2024 ASCO Genitourinary Cancers Symposium, investigators compared the efficacy of immune checkpoint inhibitor–based therapies vs sunitinib as front-line treatment in Black ...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

May 09, 2024

Belzutifan in Previously Treated Advanced Renal Cell Carcinoma

On December 14, 2023, a new treatment for unresectable locally advanced or metastatic clear cell renal cell carcinoma was approved, showing favorable outcomes compared to existing therapy.

The ASCO Post

December 27, 2023

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

On December 14, the FDA approved an HIF-2α inhibitor for patients with advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF TKI.

The ASCO Post

June 23, 2023

In Case You Missed It: Brief Highlights From Studies Presented During AACR 2023

Presented here are some highlights of preliminary studies presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. These presentations provide signals for the utility of a...

The ASCO Post

April 13, 2023

Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma Previously Treated With PD-1 or PD-L1 Inhibitors

In a U.S. phase II trial reported in The Lancet Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of the hypoxia-inducible factor 2α inhibitor belzutifan and the VEGFR kinase i...

The ASCO Post

November 13, 2023

Belzutifan Improves Outcomes for Pretreated Patients With Clear Cell Renal Cell Carcinoma Compared to Everolimus

How did treatment with a HIF-2α inhibitor compare against everolimus therapy in pretreated patients with advanced clear cell RCC? Investigators from the phase III LITESPARK-005 trial presented their f...

The ASCO Post

July 02, 2024

Perioperative Nivolumab in Renal Cell Carcinoma

The phase III PROSPER ECOG-ACRIN EA8143 trial investigated potential benefit with perioperative nivolumab vs observation in patients undergoing nephrectomy for high-risk renal cell carcinoma.

The ASCO Post